Received for publication January 30, 2006.
Revised March 22, 2006.
Accepted for publication March 24, 2006.

Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice

Abstract

Previous studies indicate that agonists of the group II metabotropic glutamate receptors (mGluRs), mGluR2 and mGluR3, may provide a novel approach for the treatment of anxiety disorders and schizophrenia. However, the relative contributions of the mGluR2 and mGluR3 subtypes to the effects of the group II mGluR agonists remain unclear. In the present study, we describe an alternate synthesis and further pharmacological characterization of a recently reported positive allosteric modulator of mGluR2, termed here biphenyl-indanone A (BINA). In recombinant systems, BINA produced a robust and selective potentiation of the response of mGluR2 to glutamate with no effect on the glutamate response of other mGluR subtypes. In hippocampal brain slices, BINA (1 µM) significantly potentiated the mGluR2/3 agonist-induced inhibition of excitatory synaptic transmission at the medial perforant path-dentate gyrus synapse. BINA was also efficacious in several models predictive of antipsychotic- and anxiolytic-like activity in mice. The behavioral effects of BINA were blocked by the mGluR2/3 antagonist LY341495, suggesting that the in vivo effects of BINA are mediated by increased activation of mGluR2. Collectively, these results indicate that BINA is a selective mGluR2 positive allosteric modulator and provide further support for the growing evidence that selective allosteric potentiators of mGluR2 mimic many of the in vivo actions of mGluR2/3 agonists that may predict therapeutic utility of these compounds.

Key words: allosteric potentiator, anxiety, glutamate, group II metabotropic glutamate receptors, mGluR2, schizophrenia

This article has been cited by other articles:

				A. E. Brady, C. K. Jones, T. M. Bridges, J. P. Kennedy, A. D. Thompson, J. U. Heiman, M. L. Breininger, P. R. Gentry, H. Yin, S. B. Jadhav, et al. Centrally Active Allosteric Potentiators of the M4 Muscarinic Acetylcholine Receptor Reverse Amphetamine-Induced Hyperlocomotor Activity in Rats J. Pharmacol. Exp. Ther., December 1, 2008; 327(3): 941 - 953. [Abstract] [Full Text] [PDF]

				P. Harrison, L. Lyon, L. Sartorius, P. Burnet, and T. Lane Review: The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia J Psychopharmacol, May 1, 2008; 22(3): 308 - 322. [Abstract] [PDF]

				Y. Chen, C. Goudet, J.-P. Pin, and P. J. Conn N-{4-Chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA) Acts through a Novel Site as a Positive Allosteric Modulator of Group 1 Metabotropic Glutamate Receptors Mol. Pharmacol., March 1, 2008; 73(3): 909 - 918. [Abstract] [Full Text] [PDF]

				M. A. Benneyworth, Z. Xiang, R. L. Smith, E. E. Garcia, P. J. Conn, and E. Sanders-Bush A Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 2 Blocks a Hallucinogenic Drug Model of Psychosis Mol. Pharmacol., August 1, 2007; 72(2): 477 - 484. [Abstract] [Full Text] [PDF]

				K. Hemstapat, H. Da Costa, Y. Nong, A. E. Brady, Q. Luo, C. M. Niswender, G. D. Tamagnan, and P. J. Conn A Novel Family of Potent Negative Allosteric Modulators of Group II Metabotropic Glutamate Receptors J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 254 - 264. [Abstract] [Full Text] [PDF]

				Y. Chen, Y. Nong, C. Goudet, K. Hemstapat, T. de Paulis, J.-P. Pin, and P. J. Conn Interaction of Novel Positive Allosteric Modulators of Metabotropic Glutamate Receptor 5 with the Negative Allosteric Antagonist Site Is Required for Potentiation of Receptor Responses Mol. Pharmacol., May 1, 2007; 71(5): 1389 - 1398. [Abstract] [Full Text] [PDF]

				K. Hemstapat, T. de Paulis, Y. Chen, A. E. Brady, V. K. Grover, D. Alagille, G. D. Tamagnan, and P. J. Conn A Novel Class of Positive Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 1 Interact with a Site Distinct from That of Negative Allosteric Modulators Mol. Pharmacol., August 1, 2006; 70(2): 616 - 626. [Abstract] [Full Text] [PDF]